These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 16927304

  • 1. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
    Gleave M, Qian J, Andreou C, Pommerville P, Chin J, Casey R, Steinhoff G, Fleshner N, Bostwick D, Thomas L, Rittmaster R.
    Prostate; 2006 Nov 01; 66(15):1674-85. PubMed ID: 16927304
    [Abstract] [Full Text] [Related]

  • 2. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
    Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS.
    J Urol; 2004 Sep 01; 172(3):915-9. PubMed ID: 15310997
    [Abstract] [Full Text] [Related]

  • 3. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
    Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, Bostwick DG.
    Urology; 2005 Jan 01; 65(1):76-82. PubMed ID: 15667867
    [Abstract] [Full Text] [Related]

  • 4. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R.
    Urology; 2008 Oct 01; 72(4):808-12. PubMed ID: 18718641
    [Abstract] [Full Text] [Related]

  • 5. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 2006 Jul 01; 12(13):4072-9. PubMed ID: 16818707
    [Abstract] [Full Text] [Related]

  • 6. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
    van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA.
    Prostate; 2009 Nov 01; 69(15):1624-34. PubMed ID: 19588525
    [Abstract] [Full Text] [Related]

  • 7. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.
    Prostate; 2004 Feb 01; 58(2):130-44. PubMed ID: 14716738
    [Abstract] [Full Text] [Related]

  • 8. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
    Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R.
    Prostate Cancer Prostatic Dis; 2007 Feb 01; 10(2):149-54. PubMed ID: 17189955
    [Abstract] [Full Text] [Related]

  • 9. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct 01; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 10. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C, Gravina GL, Muzi P, Pomante R, Angelucci A, Vicentini C, Bologna M.
    J Urol; 2008 Jul 01; 180(1):367-72. PubMed ID: 18499161
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators.
    Eur Urol; 2004 Oct 01; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [Abstract] [Full Text] [Related]

  • 12. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M, Fleshner NE, Finelli A, Zlotta AR.
    Expert Rev Anticancer Ther; 2008 Jul 01; 8(7):1073-9. PubMed ID: 18588452
    [Abstract] [Full Text] [Related]

  • 13. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.
    Maria McCrohan A, Morrissey C, O'Keane C, Mulligan N, Watson C, Smith J, Fitzpatrick JM, Watson RW.
    Cancer; 2006 Jun 15; 106(12):2743-52. PubMed ID: 16703599
    [Abstract] [Full Text] [Related]

  • 14. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS.
    Urology; 2004 Sep 15; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
    Schröder FH, Bangma CH, Wolff JM, Alcaraz A, Montorsi F, Mongiat-Artus P, Abrahamsson PA, McNicholas TA, Castro RS, Nandy IM.
    BJU Int; 2009 Mar 15; 103(5):590-6. PubMed ID: 19226424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.